Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification
Authors:
- Ian KeyzorIKIan Keyzor
- Simon ShohetSSSimon Shohet
- Jeff CastelliJCJeff Castelli
- Sheela SitaramanSSSheela Sitaraman
- Biliana Veleva-RotseBiliana Veleva-Rotse
- Jill M. WeimerJWJill M. Weimer
- Brian FoxBFBrian Fox
- Tobias WillerTWTobias Willer
- Steve TuskeSTSteve Tuske
- Louise CrathorneLCLouise Crathorne
- Klara J. BelzarKBKlara J. Belzar
Open Access
- 7 August 2023
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 13 (8) , 1227
Abstract
The treatment landscape for lysosomal storage disorders (LSDs) is rapidly evolving. An increase in the number of preclinical and clinical studies in the last decade has demonstrated that pharmacological chaperones are a feasible alternative to enzyme replacement therapy (ERT) for individuals with LSDs. A systematic search was performed to retrieve and critically assess the evidence from preclinical and clinical applications of pharmacological chaperones in the treatment of LSDs and to elucidate the mechanisms by which they could be effective in clinical practice. Publications were screened according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) reporting guidelines. Fifty-two articles evaluating 12 small molecules for the treatment of seven LSDs are included in this review. Overall, a substantial amount of preclinical and clinical data support the potential of pharmacological chaperones as treatments for Fabry disease, Gaucher disease, and Pompe disease. Most of the available clinical evidence evaluated migalastat for the treatment of Fabry disease. There was a lack of consistency in the terminology used to describe pharmacological chaperones in the literature. Therefore, the new small molecule chaperone (SMC) classification system is proposed to inform a standardized approach for new, emerging small molecule therapies in LSDs.Keywords
Funding Information
- Amicus Therapeutics, Ltd.
This publication has 84 references indexed in Scilit:
- Ambroxol as a pharmacological chaperone for mutant glucocerebrosidaseBlood Cells, Molecules, and Diseases, 2013
- Ex Vivo and in Vivo Effects of Isofagomine on Acid β-Glucosidase Variants and Substrate Levels in Gaucher DiseaseJournal of Biological Chemistry, 2012
- Identification and Characterization of Pharmacological Chaperones to Correct Enzyme Deficiencies in Lysosomal Storage DisordersASSAY and Drug Development Technologies, 2011
- A pharmacogenetic approach to identify mutant forms of α‐galactosidase a that respond to a pharmacological chaperone for Fabry diseaseHuman Mutation, 2011
- An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay–Sachs or Sandhoff variants)Molecular Genetics and Metabolism, 2011
- The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β‐glucosidaseThe FEBS Journal, 2010
- Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher DiseaseJournal of Biological Chemistry, 2009
- The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease FibroblastsMolecular Therapy, 2009
- Randomized, controlled trial of miglustat in Gaucher's disease type 3Annals of Neurology, 2008
- Pyrimethamine as a Potential Pharmacological Chaperone for Late-onset Forms of GM2 GangliosidosisJournal of Biological Chemistry, 2007